Abbott And AstraZeneca Extend Relationship To Include Co-promotion Of TRILIPIX(R) (fenofibric Acid)

Abbott and AstraZeneca announced today that they have entered into an agreement for AstraZeneca to co-promote Abbott’s TRILIPIX® (fenofibric acid), a medication for use alone or in combination with a statin to treat certain lipid disorders. Under the terms of the agreement, AstraZeneca will obtain the non-exclusive right to co-promote TRILIPIX alongside Abbott in the United States, excluding Puerto Rico. Specific financial terms were not disclosed.

More: continued here

Filed under: Cholesterol on June 10th, 2009